journal article·2024-02Open access

Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple‐Negative Breast Cancer

Changxin Zhong, Rongfeng Zhu, Ting Jiang, Sheng Tian, Xiaobao Zhao, Xiaoya Wan, Shilong Jiang, Zonglin Chen, Rong Gong, Linhao He, Jin‐Ming Yang, Na Ye, Yan Cheng

Advanced Science· Volume 11· Issue 5

Abstract

Abstract Dysregulated eEF2K expression is implicated in the pathogenesis of many human cancers, including triple‐negative breast cancer (TNBC), making it a plausible therapeutic target. However, specific eEF2K inhibitors with potent anti‐cancer activity have not been available so far. Targeted protein degradation has emerged as a new strategy for drug discovery. In this study, a novel small molecule chemical is designed and synthesized, named as compound C1, which shows potent activity in degrading eEF2K. C1 selectively binds to F8, L10, R144, C146, E229, and Y236 of the eEF2K protein and promotes its proteasomal degradation by increasing the interaction between eEF2K and the ubiquitin E3 ligase βTRCP in the form of molecular glue. C1 significantly inhibits the proliferation and metastasis of TNBC cells both in vitro and in vivo and in TNBC patient‐derived organoids, and these antitumor effects are attributed to the degradation of eEF2K by C1. Additionally, combination treatment of C1 with paclitaxel, a commonly used chemotherapeutic drug, exhibits synergistic anti‐tumor effects against TNBC. This study not only generates a powerful research tool to investigate the therapeutic potential of targeting eEF2K, but also provides a promising lead compound for developing novel drugs for the treatment of TNBC and other cancers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Peptidase Inhibition and Analysis · Protein Degradation and Inhibitors · Click Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy The Second Xiangya Hospital Central South University Changsha 410011 China

Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug Changsha 410011 China

Department of Medicinal Chemistry Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences Soochow University Suzhou Jiangsu 215123 China

Department of Pharmacy Xiangya Hospital Central South University Changsha 410011 China

Department of General Surgery The Second Xiangya Hospital Central South University Changsha Hunan 410011 China

Department of Cancer Biology and Toxicology Department of Pharmacology College of Medicine and Markey Cancer Center University of Kentucky Lexington KY 40536 USA

Ministry of Education Key Laboratory of Diabetes Immunology (Central South University) Changsha 410011 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Hunan Province · Hunan Provincial Innovation Foundation for Postgraduate

References (34)

Show source-provided references
1. 10.1021/acs.jmedchem.0c0221810.1021/acs.jmedchem.0c02218 ↗
2. 10.1016/j.cell.2013.04.05510.1016/j.cell.2013.04.055 ↗
3. 10.1007/s00109-020-01917-810.1007/s00109-020-01917-8 ↗
4. 10.18632/oncotarget.1426410.18632/oncotarget.14264 ↗
5. 10.1158/1078-0432.CCR-17-195910.1158/1078-0432.CCR-17-1959 ↗
6. 10.1038/aps.2017.13910.1038/aps.2017.139 ↗
7. 10.1038/s41419-020-03153-x10.1038/s41419-020-03153-x ↗
8. 10.1136/jitc-2021-00402610.1136/jitc-2021-004026 ↗
9. 10.1074/jbc.M111.30129110.1074/jbc.M111.301291 ↗
10. 10.1038/d41573-021-00124-510.1038/d41573-021-00124-5 ↗
11. 10.1016/j.chembiol.2021.03.00710.1016/j.chembiol.2021.03.007 ↗
12. 10.1038/s41589-019-0362-y10.1038/s41589-019-0362-y ↗
13. 10.1126/scitranslmed.abh148610.1126/scitranslmed.abh1486 ↗
14. 10.1021/acs.jmedchem.1c0089510.1021/acs.jmedchem.1c00895 ↗
15. 10.1021/acschembio.0c0052010.1021/acschembio.0c00520 ↗
16. 10.1021/acs.jmedchem.0c0131310.1021/acs.jmedchem.0c01313 ↗
17. 10.1038/nrd348010.1038/nrd3480 ↗
18. 10.1038/nrd436610.1038/nrd4366 ↗
19. 10.1038/nrd433610.1038/nrd4336 ↗
20. 10.1038/nrd.2017.11110.1038/nrd.2017.111 ↗
21. 10.1016/j.jbc.2023.10481310.1016/j.jbc.2023.104813 ↗
22. 10.1039/B610213C10.1039/B610213C ↗
23. 10.1021/jm800219f10.1021/jm800219f ↗
24. 10.1074/jbc.M113.47718210.1074/jbc.M113.477182 ↗
25. 10.1016/j.prp.2021.15356810.1016/j.prp.2021.153568 ↗
26. 10.1111/jcmm.1236110.1111/jcmm.12361 ↗
27. 10.1016/j.ejmech.2020.11250510.1016/j.ejmech.2020.112505 ↗
28. 10.1016/0092-8674(91)90124-H10.1016/0092-8674(91)90124-H ↗
29. 10.1038/s41589-021-00735-410.1038/s41589-021-00735-4 ↗
30. 10.1016/S0960-9822(95)00180-110.1016/S0960-9822(95)00180-1 ↗
31. 10.2174/092986732666619101611363110.2174/0929867326666191016113631 ↗
32. 10.1186/s13058-016-0744-y10.1186/s13058-016-0744-y ↗
33. 10.1016/j.apsb.2022.02.02910.1016/j.apsb.2022.02.029 ↗
34. 10.1016/j.xcrm.2021.10050210.1016/j.xcrm.2021.100502 ↗